Despite advancements in Chimeric Antigen Receptor T-cell (CAR-T) therapy and its notable successes, relapses and non-relapse mortality (NRM) still significantly affect prognosis. These factors contribute to the ongoing complexities in achieving favorable outcomes for patients undergoing CAR-T treatment. Secondary leukemias represent a potential complication that may manifest subsequent to CAR-T treatment. Overall, secondary leukemia may account for mutations in the FLT3 gene. These mutations can induce uncontrolled proliferation of blood cells, thereby fostering the development of aggressive and refractory forms of leukemia.
Galli, E., Frioni, F., Malara, T., Attardi, E., Bellesi, S., Hohaus, S., Sica, S., Sorà, F., Chiusolo, P., FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-t Cells, <<MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES>>, 2024; 16 (1): N/A-N/A. [doi:10.4084/MJHID.2024.029] [https://hdl.handle.net/10807/296738]
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-t Cells
Galli, Eugenio
Primo
;Frioni, Filippo;Malara, Tanja;Bellesi, Silvia;Hohaus, Stefan;Sica, Simona;Chiusolo, Patrizia
2024
Abstract
Despite advancements in Chimeric Antigen Receptor T-cell (CAR-T) therapy and its notable successes, relapses and non-relapse mortality (NRM) still significantly affect prognosis. These factors contribute to the ongoing complexities in achieving favorable outcomes for patients undergoing CAR-T treatment. Secondary leukemias represent a potential complication that may manifest subsequent to CAR-T treatment. Overall, secondary leukemia may account for mutations in the FLT3 gene. These mutations can induce uncontrolled proliferation of blood cells, thereby fostering the development of aggressive and refractory forms of leukemia.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
